Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 18/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.83 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.83 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355497 | 1.00 | CASR (0.83) | CASRCYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3355494 | 1.00 | CASR (0.83) | CASRCYP2D6SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL7603298 | 0.99 | CASR (0.83) | CASRCYP2D6SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL7603308 | 0.99 | CASR (0.83) | CASRCYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3350310 | 0.95 | CASR (0.91) | CASRCYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3350307 | 0.95 | CASR (0.91) | CASRCYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3350299 | 0.95 | CASR (0.91) | CASRCYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7606034 | 0.95 | CASR (0.91) | CASRCYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7606040 | 0.95 | CASR (0.91) | CASRCYP2D6SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL7603277 | 0.95 | CASR (0.91) | CASRCYP2D6SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2141146-A1 | Calcilytic compounds | SmithKline Beecham Corporation (US) | 2010-01-06 | — | — | EP | claimed |
| EP-1254106-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-09-14 | — | — | EP | claimed |
| US-20040192741-A1 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION & NPS PHARMACEUTICALS | 2004-09-30 | — | — | US | claimed |
| US-20030018203-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-01-23 | — | — | US | claimed |
| EP-1254106-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2002-11-06 | — | — | EP | claimed |
| US-6395919-B1 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION | 2002-05-28 | — | — | US | claimed |
| EP-1070048-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-11-07 | — | — | EP | claimed |
| WO-2001053254-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-07-26 | — | — | WO | claimed |
| EP-1070048-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-24 | — | — | EP | claimed |
| WO-1999051569-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-14 | — | — | WO | claimed |
| EP-2141146-A1 | Calcilytic compounds | SmithKline Beecham Corporation (US) | 2010-01-06 | — | — | EP | disclosed |
| US-7109238-B2 | Calcilytic compounds | SMITH KLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1254106-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040192741-A1 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION & NPS PHARMACEUTICALS | 2004-09-30 | — | — | US | disclosed |
| US-20030018203-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-01-23 | — | — | US | disclosed |
| US-6395919-B1 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION | 2002-05-28 | — | — | US | disclosed |
| EP-1070048-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001053254-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-1070048-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999051569-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018203-A1 | Calcilytic compounds | SOST, CALCB, CALCR | CASR 10/4885CYP2D6 4480/4885SLC6A2 2280/4885 |
| US-20040192741-A1 | Calcilytic compounds | SOST, CALCB, CALCR | CASR 10/4885CYP2D6 4480/4885SLC6A2 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.